Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
Resverlogix (TSX:RVX) has announced that Dr. Jeffrey Cummings, founding director of the Cleveland Clinic Lou Ruvo Brain Health Center, gave an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Disease. As quoted in the press release: During the presentation, Dr. Cummings discussed certain risk factors – including diabetes, coronary heart disease and heart …
Resverlogix (TSX:RVX) has announced that Dr. Jeffrey Cummings, founding director of the Cleveland Clinic Lou Ruvo Brain Health Center, gave an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Disease.
As quoted in the press release:
During the presentation, Dr. Cummings discussed certain risk factors – including diabetes, coronary heart disease and heart failure – associated with an increased risk of cognitive decline, cognitive impairment or dementia. Furthermore, Dr. Cummings delivered the hypothesis that dementia risk in diabetes and cardiovascular disease patients is caused by transcriptional disturbances at the epigenetic level.
The presentation also highlighted the potential of the Company’s small molecule – apabetalone, a selective bromodomain and extra-terminal inhibitor – to regulate disease-associated genes, proteins and pathways related to neuroinflammation and neurodegeneration, the BETonMACE study design, the cognition subgroup study methods and patient baseline characteristics.
The BETonMACE trial is currently expected to be completed within the first half of calendar 2019. The study is an event-based trial and will continue until at least 250 major adverse cardiac events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and stroke, have occurred. Third party adjudication of all MACE events are anticipated to be available within two to three months past trial completion. The topline results of the study will be made available shortly thereafter.
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1791.05 | -18.05 | |
Silver | 19.48 | -0.50 | |
Copper | 3.43 | -0.17 | |
Palladium | 1918.50 | -19.00 | |
Platinum | 858.00 | -26.01 | |
Oil | 102.73 | -5.70 | |
Heating Oil | 3.79 | -0.15 | |
Natural Gas | 5.64 | -0.09 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.